Table.
Summary of Selected Baseline Characteristics
| Parameter | Lenvatinib plus pembrolizumab group (n = 355) | Sunitinib group (n = 357) | Lenvatinib plus everolimus group (n = 357) |
|---|---|---|---|
| Age, years | 64 (56–70) | 61 (54–69) | 62 (55–69) |
| Sex | |||
| Male | 255 (72%) | 275 (77%) | 266 (75%) |
| Female | 100 (28%) | 82 (23%) | 91 (25%) |
| Race | |||
| White | 263 (74%) | 270 (76%) | 254 (71%) |
| Black or African American | 2 (1%) | 3 (1%) | 1 (<1%) |
| Asian | 81 (23%) | 67 (19%) | 77 (22%) |
| American Indian or Alaskan native | 0 | 0 | 1 (<1%) |
| Native Hawaiian or other Pacific Islander | 0 | 0 | 1 (<1%) |
| Other | 4 (1%) | 7 (2%) | 7 (2%) |
| Missing | 5 (1%) | 10 (3%) | 16 (4%) |
| Geographic region | |||
| Western Europe or North America | 198 (56%) | 199 (56%) | 200 (56%) |
| Rest of the world | 157 (44%) | 158 (44%) | 157 (44%) |
| MSKCC prognostic risk group | |||
| Favorable | 96 (27%) | 97 (27%) | 98 (27%) |
| Intermediate | 227 (64%) | 228 (64%) | 227 (64%) |
| Poor | 32 (9%) | 32 (9%) | 32 (9%) |
| IMDC prognostic risk group | |||
| Favorable | 110 (31%) | 124 (35%) | 114 (32%) |
| Intermediate | 210 (59%) | 192 (54%) | 195 (55%) |
| Poor | 33 (9%) | 37 (10%) | 42 (12%) |
| Could not be evaluated | 2 (1%) | 4 (1%) | 6 (2%) |
Data are median (IQR) or n (%) unless otherwise stated. Percentages might not sum to 100 as result of rounding.
Adapted from Motzer and colleagues.4 Copyright © (2021) Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.
IMDC=International Metastatic Renal Cell Carcinoma Database Consortium. MSKCC=Memorial Sloan Kettering Cancer Center.